Related Experiment Video
Updated: Aug 7, 2025
Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
Exosomal miR-23b-3p from bone mesenchymal stem cells alleviates experimental autoimmune encephalomyelitis by
Jueqiong Wang1, Huanhuan Sun2, Ruoyi Guo1
1Department of Neurology, Neurological Laboratory of Hebei Province, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Abstract:
Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system and is marked by inflammation and damage to the myelin sheath surrounding nerve fibers. Recent studies have highlighted the therapeutic value of exosomes (Exos) obtained from bone marrow mesenchymal stem cells (BMSCs) in MS treatment. These BMSC-Exos contain biologically active molecules that show promising results in preclinical evaluations. The aim of this study was to investigate the mechanism of BMSC-Exos containing miR-23b-3p in both LPS-stimulated BV2 microglia and in experimental autoimmune encephalomyelitis (EAE), an animal model for MS. Exos were isolated from BMSCs, and their effects were evaluated in vitro by co-culturing with BV2 microglia. The interaction between miR-23b-3p and its downstream targets was also explored. The efficacy of BMSC-Exos was further verified in vivo by injecting the Exos into EAE mice. The results showed that BMSC-Exos containing miR-23b-3p reduced microglial pyroptosis in vivo by specifically binding to and suppressing the expression of NEK7. In vivo, BMSC-Exos containing miR-23b-3p alleviated the severity of EAE by decreasing microglial inflammation and pyroptosis via the repression of NEK7. These findings provide new insights into the therapeutic potential of BMSC-Exos containing miR-23b-3p for MS.
Insights
Bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) containing miR-23b-3p reduce inflammation and severity in multiple sclerosis (MS) models. These exosomes target NEK7, suppressing microglial pyroptosis for potential MS therapeutics.
Area of Science:
- Neuroimmunology
- Cell Biology
- Regenerative Medicine
Background:
- Multiple sclerosis (MS) is a chronic autoimmune CNS disease.
- Damage to myelin sheath and inflammation are key features of MS.
- Exosomes from bone marrow mesenchymal stem cells (BMSC-Exos) show therapeutic potential for MS.
Purpose of the Study:
- Investigate the mechanism of BMSC-Exos carrying miR-23b-3p in MS.
- Evaluate BMSC-Exos effects on LPS-stimulated BV2 microglia and EAE mouse models.
- Determine the interaction between miR-23b-3p and its downstream targets.
Main Methods:
- Isolation of exosomes from BMSCs.
- In vitro co-culture of BMSC-Exos with BV2 microglia.
- In vivo administration of BMSC-Exos in experimental autoimmune encephalomyelitis (EAE) mice.
- Analysis of microglial pyroptosis and inflammation, targeting NEK7.
Main Results:
- BMSC-Exos containing miR-23b-3p suppressed NEK7 expression in vitro.
- BMSC-Exos containing miR-23b-3p reduced microglial pyroptosis in vivo.
- Administration of BMSC-Exos alleviated EAE severity by decreasing inflammation and pyroptosis via NEK7 repression.
Conclusions:
- BMSC-Exos containing miR-23b-3p offer a potential therapeutic strategy for MS.
- The mechanism involves the suppression of NEK7, reducing microglial pyroptosis.
- These findings highlight the therapeutic value of BMSC-Exos in neuroinflammatory diseases.
